GCM
TNGX icon

Gladius Capital Management’s Tango Therapeutics TNGX Stock Holding History

Gladius Capital Management’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-8,903
Closed -$33K – 440
2022
Q3 		$33K Buy
+8,903
New +$38K ﹤0.01% 288

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Gladius Capital Management's TNGX Position: Q4 2022 in Review

Gladius Capital Management sold out of Tango Therapeutics (TNGX) in Q4 2022, closing a stake of 8,903 shares — an estimated $33K sold.

Gladius Capital Management first reported a position in TNGX in Q3 2022 and held it in 1 quarter. The position peaked at $33K in Q3 2022. 82 funds tracked by Wall St. Rank hold TNGX as of Q4 2022.

  • Gladius Capital Management reported no remaining Tango Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Gladius Capital Management sold 8,903 Tango Therapeutics shares in Q4 2022, an estimated $33K.
  • Gladius Capital Management first reported a position in Tango Therapeutics in Q3 2022 and held it in 1 quarter.
  • Gladius Capital Management's Tango Therapeutics position peaked at $33K in Q3 2022.
  • 82 funds tracked by Wall St. Rank held Tango Therapeutics as of Q4 2022.

Based on Gladius Capital Management's 13F filing for Q4 2022, filed 2 Feb 2023.